uniQure’s (QURE) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of uniQure (NASDAQ:QURE) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a $70.00 price objective on the biotechnology company’s stock.

Other analysts have also issued reports about the stock. Chardan Capital restated a “buy” rating and set a $35.00 target price on shares of uniQure in a research report on Friday, August 29th. Mizuho upgraded shares of uniQure from a “neutral” rating to an “outperform” rating and set a $30.00 target price for the company in a research report on Thursday, August 14th. Cantor Fitzgerald set a $47.00 target price on shares of uniQure in a research report on Wednesday, July 30th. Guggenheim restated a “buy” rating and set a $28.00 target price on shares of uniQure in a research report on Monday, May 12th. Finally, Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, August 2nd. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, uniQure currently has an average rating of “Buy” and a consensus price target of $37.45.

uniQure Stock Performance

Shares of NASDAQ QURE opened at $17.95 on Friday. The firm has a 50 day moving average of $14.98 and a 200 day moving average of $13.81. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. The firm has a market capitalization of $984.92 million, a price-to-earnings ratio of -4.58 and a beta of 0.13. uniQure has a 12-month low of $4.45 and a 12-month high of $19.18.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.20. The company had revenue of $5.26 million during the quarter, compared to analyst estimates of $5.00 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. On average, research analysts anticipate that uniQure will post -3.75 earnings per share for the current year.

Insider Transactions at uniQure

In other uniQure news, Director David D. Meek sold 2,112 shares of the stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total transaction of $30,518.40. Following the completion of the transaction, the director owned 34,190 shares in the company, valued at $494,045.50. This trade represents a 5.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Jeannette Potts sold 4,670 shares of the company’s stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $15.14, for a total transaction of $70,703.80. Following the sale, the insider owned 115,073 shares in the company, valued at $1,742,205.22. This represents a 3.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,144 shares of company stock valued at $322,426. 4.79% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On uniQure

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC grew its holdings in uniQure by 358.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 5,538 shares in the last quarter. Mraz Amerine & Associates Inc. bought a new position in uniQure during the 1st quarter worth about $106,000. KLP Kapitalforvaltning AS bought a new position in uniQure during the 2nd quarter worth about $117,000. Teacher Retirement System of Texas bought a new position in uniQure during the 2nd quarter worth about $151,000. Finally, OMERS ADMINISTRATION Corp bought a new position in uniQure during the 1st quarter worth about $152,000. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.